

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
12582

In Re Application Of: Lloyd S. Gray, et al.

Serial No.
09/544,968

Filing Date
April 7, 2000

Examiner
Unassigned

Group Art Unit
Unassigned

Title: **ANTICANCER CALCIUM CHANNEL BLOCKERS**

RECEIVED

NOV 21 2000

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1000/200

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
12582

In Re Application Of: Lloyd S. Gray, et al.

Serial No.
09/544,968

Filing Date
April 7, 2000

Examiner
Unassigned

Group Art Unit
Unassigned

Title: ANTICANCER CALCIUM CHANNEL BLOCKERS



RECEIVED
NOV 21 2000

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-3886/RCT as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. _____) on _____

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 11/13/00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Janet Giordano
Signature of Person Mailing Correspondence

Janet Giordano

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Mark J. Cohen
Signature

Mark J. Cohen
Registration No. 32,211

Dated: November 13, 2000

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516)742-4343

CC:



PATENTS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lloyd S. Gray, et al.

Examiner: Unassigned

Serial No: 09/544,968

Art Unit: Unassigned

Filed: April 7, 2000

Docket: 12582

For: ANTICANCER CALCIUM CHANNEL
BLOCKERS

Dated: November 13, 2000

Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

RECEIVED
NOV 21 2000
TECH CENTER (602/PS00)

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. §§1.56, 1.97 and 1.98, applicants are making of record art for consideration by the United States Patent and Trademark Office. Some of this art was encountered in the course of the prosecution of the corresponding PCT application, and is cited in the International Search Report, a copy of which is enclosed herewith.

The cited art is specifically listed on the accompanying PTO-1449 and
hereinbelow:

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on November 13, 2000.

Dated: November 13, 2000

Janet Giordano
Janet Giordano

U.S. Patent No. 3,732,247, issued May 8, 1973, to Helsley, et al.

U.S. Patent No. 4,908,365, issued March 13, 1990, to Buzas, et al.

U.S. Patent No. 4,957,927, issued September 18, 1990 to Ferrand, et al.

International Application No. WO 97/10212.

International Application No. WO 92/05172.

European Patent No. EP 0 805 147 A1.

Benzaquen, Laura R., et al. "Clotrimazole inhibits cell proliferation in vitro and in vivo", Nature Medicine, Vol. 1, No. 6, June 1995, pp. 524-540.

Cohen, R.B., et al. "Pilot study of pharmacologic inhibition of calcium entry blockers in the treatment of advanced breast and prostate cancer", Proc. Annu. Meet. Am. Soc. Clin. Oncol., Vol. 16, 1997, p. 538a.

Densmore John J., et al. "A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes", Febs Letters, Vol. 312, No. 2,3, Nov. 1992, p. 161-164.

Densmore, John J., et al. "A voltage-operable current is involved in Ca^{2+} entry in human lymphocytes whereas I_{CRAC} has no apparent role", Am. J. Physiol., Vol. 271, (1996).

Haverstick, Doris M., "Calmodulin regulation of Ca^{2+} entry in Jurkat T cells", Cell Calcium, 23(6):361-367, 1998.

Wikstrom, Peter, et al. "Additional peptidyl diazomethyl ketones, including biotinyl derivatives, which affinity-label calpain and related cysteinyl proteinases", J. Enzyme Inhibition, 1993, Vol. 6, pp. 259-269.

International Search Report (International Application No. PCT/US00/09310).

For the convenience of the United States Patent and Trademark Office, a copy of each of the publications listed hereinabove is enclosed herewith.

Consideration of this Information Disclosure Statement is respectfully requested since the art provided may be material to the examination of the present application, as defined in 37 C.F.R. §1.56.

RECEIVED
NOV 21 2000
TECH CENTER (600/2800)

Inasmuch as this Information Disclosure Statement is being submitted prior to the issuance of a first Official Action on the merits, no fee or certificate is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark J. Cohen". The signature is fluid and cursive, with the first name "Mark" being more prominent.

Mark J. Cohen
Registration No. 32,211

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530

MJC/bb